InvestorsHub Logo
Followers 14
Posts 205
Boards Moderated 0
Alias Born 02/15/2016

Re: Rogerthat1 post# 13659

Wednesday, 03/02/2016 8:11:17 PM

Wednesday, March 02, 2016 8:11:17 PM

Post# of 34625
While the vaccine will not be the same, it is nonetheless demonstrating similar technology and similar approach. Investors look at this. This is also why TPIV will stand to benefit from Galena succeeding with Neuvax. Immuno oncology has been fighting an uphill battle for legitimacy for a while now, and the more positive data that's out there, the better it'll be for the sub-sector.

If it fails, it could have a dampening effect on expectations across the board.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent MRKR News